Brian Wilson
BiotechWilson
Shrewd biotech investor, research consultant, numbers guy.
Recent Articles by Brian Wilson
Jul 22, 2014
by Brian Wilson
Why Investors Continue to Flee Aegerion Stock
In theory Aegerion could still reach this peaks sales figure (quite easily) given that there are many more reimbursable HoFH patients out there, but it appears that Amgen’s (AMGN) hugely successful PCSK9 inhibitor evolocumab will dethrone Juxtapid before that happens.
Jun 30, 2014
by Brian Wilson
Why Teva's Magic Bullet Could Misfire
But with the recent loss of its lawsuit against the FDA's approval of these generic (which was meant to block competing glatiramer acetate formulations without additional bioequivalency trial data) it’s clear that the new 40 mg/mL formulation of Copaxone is now the only thing preventing Teva’s Copaxone brand from totally losing its market share in multiple sclerosis given its current price.
Jun 23, 2014
by Brian Wilson
Bristol-Myers Squibb's Oncology Opportunity
But despite all the challenging facing Bristol-Myers today, I do believe the positioned to do extremely well in oncology due to the commercial potential of Sprycel (dasatinib) and Yervoy (ipilimumab). Both drugs have been growing sales rapidly throughout the last year, and have no patent concerns in the short run.
HOW THE MOTLEY FOOL CAN HELP YOU
-
Premium Investing Guidance
Market beating stocks from our award-winning service
-
The Daily Upside Newsletter
Investment news and high-quality insights delivered straight to your inbox
-
Get Started Investing
You can do it. Successful investing in just a few steps
-
Win at Retirement
Secrets and strategies for the post-work life you want.
-
Find a Broker
Find the right brokerage account for you.
-
Listen to our Podcasts
Hear our experts take on stocks, the market, and how to invest.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.